The expression of G protein‐coupled receptor, class C Group 5 member D (GPRC5D), on the surface of myeloma tumor cells makes it a possible target for relapse/refractory multiple myeloma therapy, and relevant studies are in progress. This evidence concerns the gene GPRC5D and neoplasm.